Frontlight ResearchEarly access
Taking people in United StatesPhase 1/2
A Study of Tagmokitug in Combination With Other Treatments in Participants With Advanced or Metastatic Solid Tumors
Key facts
- Who runs it
- Coherus Oncology, Inc.
- Where
- Seattle, United StatesSee the site
- Trial code
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 12 people, planned
- Started
- Nov 2026
- Expected to end
- Aug 2028
- Type of study
- Interventional
- Treatments tested
- Tagmokitug
- Pasritamig
- Record updated
- 18 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Men only
- Healthy volunteers
- Cannot take part
Show the full registry criteria (14)Hide the full registry criteria
Who can take part
- Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1
- Resolved acute effects of any prior therapy to baseline severity or Grade 1 in accordance with National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0, except for adverse events (AEs) not constituting a safety risk per Investigator judgment; mCRPC:
- Histologically confirmed adenocarcinoma of the prostate. Adenocarcinoma with focal small cell or neuroendocrine (NE) features based on immunohistochemistry (IHC) alone is permitted. However, small cell carcinoma, carcinoid tumor, mixed NE carcinoma, or large cell NE carcinoma is not permitted
- Measurable Castration-resistant Prostate Cancer (mCRPC) as defined by PCWG3 criteria. Participant must have mCRPC that is metastatic either to bone, lymph node (LN), or both without clear evidence of either measurable or nonmeasurable metastasis to visceral organs at the time of screening scan
- Participants must have been previously treated with at least 1 prior androgen-receptor pathway inhibitor (ARPI) (ie, abiraterone acetate, enzalutamide, apalutamide, darolutamide)
- Participants must have received at least one prior taxane therapy unless the participant is ineligible or refused. Participants must not have received other prior cytotoxic chemotherapy (ie, cisplatin, carboplatin, etoposide)
- Prior orchiectomy or medical castration. Participants who have not undergone orchiectomy, must be receiving ongoing androgen deprivation therapy (ADT) with a gonadotropin-releasing hormone (GnRH) analog with testosterone ≤50 nanogram per deciliter (ng/dL) prior to the first dose of study drug and must continue this therapy throughout the treatment phase
Who cannot take part
- Prior exposure to anti-CCR8 antibody agents
- Prior allogeneic hematological stem cell transplantation or organ transplantation; mCRPC:
- Any known prior history of brain metastases of prostate cancer (PCa)
- Treatment with antineoplastic therapy (including but not limited to cytotoxic chemotherapy, biologic agents, and investigational agents) other than ADT or ARPI within 28 days or <5× the elimination half-life (t½), whichever is earlier, before Day 1
- Prior exposure to a T cell engager or human kallikrein 2 (KLK2) targeted therapy
- Major surgery requiring general anesthesia within 28 days prior to the first dose of study treatment, still recovering from prior surgery, or with surgery scheduled during the study; Additional protocol-defined inclusion and exclusion criteria apply
- History of prior malignancy other than the cancer under study that is progressing or has required active treatment within the past 3 years
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Sex
- Solid tumor
This trial is currently available in United States.
- Fred Hutchinson Cancer CenterSeattle, United StatesContact: Clinical Operations TeamTaking people
About the trial
What the trial wants to find out
The primary purpose of this study is to evaluate the safety and tolerability of tagmokitug in combination with other therapies.
The group in the trial
- mCRPC: Tagmokitug + PasritamigTreatment being tested
Treatment: Tagmokitug and Pasritamig
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 3 eligibility questions with room for answers and notes.
Download the PDF
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1/2, Multicenter, Open-Label, Multicohort Study Evaluating the Safety and Efficacy of Tagmokitug in Combination With Other Treatments in Participants With Advanced or Metastatic Solid Tumors
- Criteria questions
- Built from NCT07945821, who can take part
- Record updated
- 18 November 2026